MedPacto, Inc. (KOSDAQ: 235980)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,200.00
-155.00 (-3.56%)
Jan 17, 2025, 9:00 AM KST
-48.21%
Market Cap 137.79B
Revenue (ttm) n/a
Net Income (ttm) -23.31B
Shares Out 34.28M
EPS (ttm) -761.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 108,225
Average Volume 125,500
Open 4,315.00
Previous Close 4,355.00
Day's Range 4,190.00 - 4,335.00
52-Week Range 4,000.00 - 17,240.00
Beta 0.73
RSI 27.48
Earnings Date Mar 19, 2025

About MedPacto

MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Seong-Jin Kim
Employees 56
Stock Exchange KOSDAQ
Ticker Symbol 235980
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.